These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 15282442)

  • 1. Cardiovascular complications in acromegaly.
    Vitale G; Pivonello R; Lombardi G; Colao A
    Minerva Endocrinol; 2004 Sep; 29(3):77-88. PubMed ID: 15282442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acromegaly and the cardiovascular system.
    Lombardi G; Galdiero M; Auriemma RS; Pivonello R; Colao A
    Neuroendocrinology; 2006; 83(3-4):211-7. PubMed ID: 17047385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The GH-IGF-I axis and the cardiovascular system: clinical implications.
    Colao A
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac abnormalities in acromegaly. Pathophysiology and implications for management.
    Vitale G; Pivonello R; Lombardi G; Colao A
    Treat Endocrinol; 2004; 3(5):309-18. PubMed ID: 15330678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly.
    Lombardi G; Colao A; Marzullo P; Ferone D; Longobardi S; Esposito V; Merola B
    J Endocrinol; 1997 Oct; 155 Suppl 1():S33-7; discussion S39. PubMed ID: 9389993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone, acromegaly, and heart failure: an intricate triangulation.
    Saccà L; Napoli R; Cittadini A
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):660-71. PubMed ID: 14974906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5 Long-term acromegaly and associated cardiovascular complications: a case-based review.
    Colao A
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23 Suppl 1():S31-8. PubMed ID: 20129192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.
    Bogazzi F; Di Bello V; Palagi C; Donne MG; Di Cori A; Gavioli S; Talini E; Cosci C; Sardella C; Brogioni S; Mariani M; Martino E
    Clin Endocrinol (Oxf); 2005 May; 62(5):590-6. PubMed ID: 15853830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular involvement in patients affected by acromegaly: an appraisal.
    Mosca S; Paolillo S; Colao A; Bossone E; Cittadini A; Iudice FL; Parente A; Conte S; Rengo G; Leosco D; Trimarco B; Filardi PP
    Int J Cardiol; 2013 Sep; 167(5):1712-8. PubMed ID: 23219077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.
    Fatti LM; Scacchi M; Lavezzi E; Pecori Giraldi F; De Martin M; Toja P; Michailidis G; Stramba-Badiale M; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):626-30. PubMed ID: 17054464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heart disease in acromegaly. Study of 27 patients].
    Marín F; Picó AM; Martínez JG; Domínguez JR; Alfayete R; Sogorb F
    Med Clin (Barc); 1996 Sep; 107(9):326-30. PubMed ID: 8984234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular involvement in acromegaly. Apropos of 3 cases].
    Cosnay P; Legras A; Garnier LF; Moquet B; Casset D; Fauchier JP; Brochier M
    Arch Mal Coeur Vaiss; 1987 Oct; 80(11):1643-50. PubMed ID: 3128208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiovascular disturbances in acromegaly].
    Fedrizzi D; Czepielewski MA
    Arq Bras Endocrinol Metabol; 2008 Dec; 52(9):1416-29. PubMed ID: 19197449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.